Literature DB >> 15811161

Amantadine for traumatic brain injury: does it improve cognition and reduce agitation?

H Leone1, B W Polsonetti.   

Abstract

OBJECTIVE: To review the available literature pertaining to amantadine as therapy for improving cognition and reducing agitation following a non-penetrating traumatic brain injury (TBI). DATA SOURCES: Clinical literature was accessed through MEDLINE (from 1966 to February 2004) and bibliographic searches. Key search terms included 'amantadine', 'traumatic brain injury', 'cognition', and 'agitation'. DATA SYNTHESIS: Amantadine is primarily used for treatment and prophylaxis of influenza A. Its ability to improve mentation and motor function in patients with head injury remains questionable. An evaluation of five clinical trials, two case reports, and one case series is conducted focusing on the use of amantadine following TBI. Patients in clinical trials were assessed using a variety of neuropsychological tools aimed at, among other things, assessing cognition and agitation. Although individual patient results varied, the majority of patients studied showed improved neuropsychological test scores. Similar observations are noted in the case reports and case series. Improvement in cognition and reduced agitation seems to occur with post-injury amantadine therapy.
CONCLUSIONS: Amantadine is a reasonable option for improving cognition and reducing agitation following a TBI but confirmatory evidence of the efficacy the drug is necessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811161     DOI: 10.1111/j.1365-2710.2005.00628.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  9 in total

Review 1.  Medical therapies for concussion.

Authors:  William P Meehan
Journal:  Clin Sports Med       Date:  2011-01       Impact factor: 2.182

2.  Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].

Authors:  Bernardino Ossola; Nadia Schendzielorz; Shih-Heng Chen; Gary S Bird; Raimo K Tuominen; Pekka T Männistö; Jau-Shyong Hong
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

Review 3.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

4.  Cerebellar mutism syndrome and its relation to cerebellar cognitive and affective function: Review of the literature.

Authors:  Ozlem Yildiz; Serdar Kabatas; Cem Yilmaz; Nur Altinors; Belma Agaoglu
Journal:  Ann Indian Acad Neurol       Date:  2010-01       Impact factor: 1.383

5.  Assessment of therapeutic potential of amantadine in methamphetamine induced neurotoxicity.

Authors:  Bessy Thrash-Williams; Manuj Ahuja; Senthilkumar S Karuppagounder; Subramaniam Uthayathas; Vishnu Suppiramaniam; Muralikrishnan Dhanasekaran
Journal:  Neurochem Res       Date:  2013-08-06       Impact factor: 3.996

Review 6.  Psychiatric manifestations of neurologic disease: where are we headed?

Authors:  Constantin G Lyketsos; Nicholas Kozauer; Peter V Rabins
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

7.  The Effect of Oral Administration of Amantadine on Neurological Outcome of Patients With Diffuse Axonal Injury in ICU.

Authors:  Rahman Abbasivash; Mohammad Amin Valizade Hasanloei; Aidin Kazempour; Ata Mahdkhah; Mir Mehdi Shaaf Ghoreishi; Ghazal Akhavan Masoumi
Journal:  J Exp Neurosci       Date:  2019-01-27

8.  Placebo-controlled trial of oral amantadine and zolpidem efficacy on the outcome of patients with acute severe traumatic brain injury and diffuse axonal injury.

Authors:  Sajad Shafiee; Saeed Ehteshami; Mahmood Moosazadeh; Saeed Aghapour; Kaveh Haddadi
Journal:  Caspian J Intern Med       Date:  2022

9.  Amantadine Did Not Positively Impact Cognition in Chronic Traumatic Brain Injury: A Multi-Site, Randomized, Controlled Trial.

Authors:  Flora M Hammond; Mark Sherer; James F Malec; Ross D Zafonte; Sureyya Dikmen; Jennifer Bogner; Kathleen R Bell; Jason Barber; Nancy Temkin
Journal:  J Neurotrauma       Date:  2018-06-07       Impact factor: 5.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.